Profile data is unavailable for this security.
About the company
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-20.62m
- Incorporated2011
- Employees6.00
- LocationNeximmune Inc9119 Gaither RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (301) 825-9810
- Fax+1 (302) 636-5454
- Websitehttps://www.neximmune.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Meso Numismatics Inc | 2.87m | -10.15m | 344.70k | 1.00 | -- | -- | -- | 0.12 | -0.8144 | -0.8144 | 0.2303 | -2.07 | 0.5424 | -- | 76.15 | -- | -191.67 | -192.08 | -- | -- | 68.95 | 60.24 | -353.35 | -821.49 | 0.0257 | -0.0755 | -- | -- | 57.49 | 116.97 | -76.03 | -- | 149.35 | -- |
Cannabis Global, Inc. | 2.62m | -3.16m | 431.88k | 3.00 | -- | 0.0172 | -- | 0.1649 | -0.0324 | -0.0324 | 0.008 | 0.0058 | 0.1929 | 14.13 | 5.92 | -- | -27.77 | -164.57 | -140.92 | -- | -2.45 | -- | -143.95 | -831.07 | 0.1799 | -1.75 | 0.3238 | -- | 5,829.78 | -- | -58.94 | -- | -- | -- |
Neximmune Inc | 0.00 | -20.62m | 443.80k | 6.00 | -- | 0.6373 | -- | -- | -18.59 | -18.59 | 0.00 | 0.66 | 0.00 | -- | -- | 0.00 | -140.56 | -115.07 | -224.94 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
VBI Vaccines Inc | 9.41m | -83.99m | 493.34k | 131.00 | -- | -- | -- | 0.0524 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
Endonovo Therapeutics Inc | 255.72k | -4.40m | 515.88k | 0.00 | -- | -- | -- | 2.02 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
NovAccess Global Inc | 0.00 | -1.74m | 522.50k | 1.00 | -- | -- | -- | -- | -0.1193 | -0.1193 | 0.00 | -0.2246 | 0.00 | -- | -- | 0.00 | -1,836.30 | -2,185.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -177.93 | -- | -- | -- |
Capstone Therapeutics Corp | 0.00 | -358.00k | 535.87k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
Herborium Group, Inc. | 340.33k | -318.65k | 545.97k | 2.00 | -- | -- | -- | 1.60 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
International Stem Cell Corp | 8.32m | -529.00k | 564.31k | 29.00 | -- | -- | -- | 0.0678 | -0.0661 | -0.0661 | 1.04 | 0.0355 | 1.46 | 2.54 | 11.31 | 286,965.50 | -12.02 | -29.22 | -84.86 | -73.82 | 58.62 | 59.49 | -8.22 | -21.01 | 0.4785 | -3.94 | 0.9254 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
Yield10 Bioscience Inc | 750.00k | -12.70m | 635.87k | 29.00 | -- | -- | -- | 0.8478 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
Holder | Shares | % Held |
---|---|---|
Sabby Management LLCas of 31 Mar 2024 | 59.85k | 4.37% |
Slate Path Capital LPas of 31 Mar 2024 | 37.00k | 2.70% |
EPIQ Capital Group LLCas of 30 Jun 2024 | 15.62k | 1.14% |
PNC Bank, NA (Investment Management)as of 30 Jun 2024 | 12.64k | 0.92% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 12.01k | 0.88% |
Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 2024 | 10.80k | 0.79% |
Geode Capital Management LLCas of 30 Jun 2024 | 6.75k | 0.49% |
Tower Research Capital LLCas of 31 Mar 2024 | 1.58k | 0.12% |
Dimensional Fund Advisors LPas of 30 Apr 2024 | 1.16k | 0.08% |
RBC Dominion Securities, Inc.as of 31 Mar 2024 | 173.00 | 0.01% |